Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Checkmate Pharmaceuticals, Inc. (CMPI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/10/2022 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 06/07/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/07/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/03/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/03/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 06/02/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/31/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/31/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/31/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/31/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/31/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/31/2022 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 05/31/2022 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/31/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/20/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/20/2022 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/11/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/02/2022 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 05/02/2022 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Checkmate Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Scandinavian Acquisition Sub, Inc",
"Tender and Support Agreement, by and among Regeneron Pharmaceuticals, Inc., Scandinavian Acquisition Sub, Inc. and certain Stockholders of Checkmate Pharmaceuticals, Inc" |
|
| 04/19/2022 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 04/19/2022 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 04/19/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/01/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G
| Decheng Capital Management III , LLC reports a 6.2% stake in Checkmate Pharamaceuticals, Inc. |
| 02/14/2022 |
SC 13G/A
| CLOUGH CAPITAL PARTNERS L P reports a 5.3% stake in Checkmate Pharmaceuticals, Inc. |
| 02/09/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors January 31, 2022 CAMBRIDGE, Mass., Jan. 31, 2022 — Checkmate Pharmaceuticals, Inc . , a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors . “Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immuno-oncology development portfolios,” said Alan Fuhrman, Interim CEO and President of Checkmate. “We are thrilled to strengthen Checkmate's Board by leveraging Jon's broad experience across academia, government and the biopharmaceutical indu..." |
|
| 12/21/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|